Please assess the completion status of the following clinical trial:

Trial Title: Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed epithelial ovarian cancer, primary peritoneal serous cancer, papillary serous endometrial cancer, or fallopian tube cancer~* Must have responded and remained clinically stable (as defined by normal clinical examination, normal serum CA125 level and normal CT scan) after first-line platinum-based regimen followed by bevacizumab maintenance therapy~* Must have developed relapsed disease at least 3 months after completion of bevacizumab maintenance therapy as defined by a) development of new, measurable lesions by RECIST criteria, but no lesion with maximum diameter greater than 3 centimeters OR b) newly elevated CA125 level at least 2 x ULN on 2 separate occasions, obtained at least 1 day but not more than 3 months apart~* ECOG Performance Status 0-2~* No prior cytotoxic chemotherapy or biologic therapy for disease recurrence allowed~* Prior hormonal-based therapy for ovarian, primary peritoneal serous or fallopian tube cancer is allowed~* Toxic side effects related to prior chemotherapy or hormonal therapy must have resolved to grade one or less or to baseline before initiation of bevacizumab~* 18 years of age or older~* Life expectancy of 6 months or greater~* Normal organ and marrow function as outlined in the protocol~Exclusion Criteria:~* Prior cytotoxic chemotherapy or biologic therapy for disease recurrence~* Known CNS disease, except for treated brain metastasis~* Pregnancy or breast feeding~* Uncontrolled intercurrent illness including, but not limited to hypertension, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0, or anticipation of need for major surgical procedure during the course of the study~* Core biopsy or other minor surgical procedure, excluding placement of a vascular device, within 7 days prior to enrollment~* History of abdominal fistula, GI perforation, intra-abdominal abscess, or CT evidence of bowel obstruction or bowel wall thickening~* Symptoms of intestinal obstruction, or requirement of parenteral hydration and/or nutrition~* History of active malignancy during the last 3 years, except non-melanomatous skin cancer or in situ breast or cervical cancer~* Evidence of preexisting uncontrolled hypertension. If patient has hypertension, it must be medically controlled (\< 150/90) prior to starting bevacizumab~* Proteinuria at screening~* Dementia or significantly altered mental status that would prohibit the understanding and/or giving of informed consent~* Therapeutic anticoagulation is not by itself and exclusion criterion. However, for certain high risk patients on therapeutic anticoagulation, eligibility will be determined after discussion with the overall PI~* Any active bleeding~* Serious, non-healing wound, ulcer, or bone fracture~* Prior history of hypertensive crisis or hypertensive encephalopathy~* NYHA Grade II or greater congestive heart failure~* History of myocardial infarction or unstable angina within 6 months prior to Day 1~* History of stroke or transient ischemic attack within 6 months prior to day 1~* Significant vascular disease within 6 months prior to day 1~* History of hemoptysis within 1 month prior to day 1~* Presence of measurable lesion(s) by RECIST criteria with maximum diameter greater than 3 centimeters

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- bevacizumab (Type: EXPERIMENTAL): Bevacizumab was administered at 15 mg/kg intravenously every 3 weeks. Treatment continued until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).